MedWatch

Lundbeck and partner expand collaboration

The Danish company Lundbeck and its Japanese partner Osuka have decided to expand their current partnership in the EU.

Japanese Otsuka and Danish Lundbeck will work more closely in their efforts to develop and market new drugs for a range of neurological disorders, the Danish company informs in a stock market release.

As of April 1 the two companies will be co-marketing the pill Abilify for the treatment of schizophrenia in 14 European countries including Denmark, Finland, Germany, Italy, Spain and the UK. Lundbeck will market the drug on its own in Austria, Belgium, Ireland, the Netherlands, Poland and Romania.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier